Metallothioneins and brain injury: What transgenic mice tell us

Environmental Health and Preventive Medicine

Volumn 9, Issue 3, 2004, Pages 87-94

  Hidalgo, Juan ^a  

^a INSTITUT DE NEUROCIÈNCIES   (Spain)

Author keywords

Brain injury; Cytokines; Metallothionein; Oxidative stress; Transgenic mice

Indexed keywords

ANTIOXIDANT; GROWTH INHIBITOR; INHIBITOR OF APOPTOSIS PROTEIN; METALLOTHIONEIN; METALLOTHIONEIN 4; METALLOTHIONEIN I; METALLOTHIONEIN II; METALLOTHIONEIN III; UNCLASSIFIED DRUG;

BRAIN INJURY; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; EPITHELIUM; KERATINIZATION; MOUSE; NERVE GROWTH; NERVE SPROUTING; NERVOUS SYSTEM INJURY; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW; TRANSGENIC MOUSE;

MUS MUSCULUS; RODENTIA;

EID: 3042785091     PISSN: 1342078X     EISSN: None     Source Type: Journal    
DOI: 10.1265/ehpm.9.87     Document Type: Review

References (155)

1. Margoshes M, Vallee BL. A cadmium protein from equine kidney cortex. J. Amer. Chem. Soc. 1957; 79: 4813-4814.
2. Kägi JHR, Vallee BL. Metallothionein: a cadmium- and zinc-containing protein from equine renal cortex. J. Biol. Chem. 1960; 235: 3460-3465.
3. Kägi JHR, Valle BL. Metallothionein: a cadmium- and zinc-containing protein from equine renal cortex. II. Physicochemical properties. J. Biol. Chem. 1961; 236: 2435-2442.
4. Hamer DH. Metallothionein. Annu. Rev. Biochem. 1986; 55: 913-951.
5. Bremner I. Interactions between metallothionein and trace elements. Prog. Food Nutr. Sci. 1987; 11: 1-37.
6. Vašák M, Hasler DW. Metallothioneins: new functional and structural insights. Current Opinion Chem. Biol. 2000; 4: 177-183.
7. Andrews GK. Regulation of metallothionein gene expression by oxidative stress and metal ions. Biochem. Pharmacol. 2000; 59: 95-104.
8. Ghoshal K, Jacob ST. Regulation of metallothionein gene expression. Prog. Nucleic. Acid. Res. Mol. Biol. 2001; 66: 357-384.
9. Coyle P, Philcox JC, Carey LC, Rofe AM. Metallothionein: the multipurpose protein. Cell Mol. Life Sci. 2002; 59: 627-647.
10. Binz P-A, Kägi JHR. (1999) Metallothionein: Molecular evolution and classification. In: Metallothionein IV (ed. CD Klaassen), pp 7-13. Birkhäuser Verlag, Basel.
11. Palmiter RD, Findley SD, Whitmore TE, Durnam DM. MT-III, a brain-specific member of the metallothionein gene family. Proc. Natl. Acad. Sci. USA 1992; 89: 6333-6337.
12. Quaife CJ, Findley SD, Erickson JC, et al. Induction of a new metallothionein isoform (MT-IV) occurs during differentiation of stratified squamous epithelia. Biochemistry 1994; 33: 7250-7259.
13. West AK, Stallings R, Hildebrand CE, Chiu R, Karin M, Richards RI. Human metallothionein genes: structure of the functional locus at 16q13. Genomics 1990; 8: 513-518.
14. Samson SL, Gedamu L. Molecular analyses of metallothionein gene regulation. Prog. Nucleic Acid Res. Mol. Biol. 1998; 59: 257-288.
15. Searle PF, Davison BL, Stuart GW, Wilkie TM, Norstedt G, Palmiter RD. Regulation, linkage, and sequence of mouse metallothionein I and II genes. Mol. Cell. Biol. 1984; 4: 1221-1230.
16. Yagle MK, Palmiter RD. Coordinate regulation of mouse metallothionein I and II genes by heavy metals and glucocorticoids. Mol. Cell. Biol. 1985; 5: 291-294.
17. van Lookeren Campagne M, Thiobodeaux H, van Bruggen N, Cairns B, Lowe DG. Increased binding activity at an antioxidant-responsive element in the metallothionein-1 promoter and rapid induction of metallothionein-1 and -2 in response to cerebral ischemia and reperfusion. J. Neurosci. 2000; 20: 5200-5207.
18. Durnam DM, Palmiter RD. Transcriptional regulation of the mouse metallothionein-I gene by heavy metals. J. Biol. Chem. 1981; 256: 5712-5716.
19. Blaauwgeers HG, Sillevis Smitt PA, De Jong JM, Troost D. Distribution of metallothionein in the human central nervous system. Glia 1993; 8: 62-70.
20. Gulati S, Paliwal VK, Sharma M, Gill KD, Nath R. Isolation and characterization of a metallothionein-like protein from monkey brain. Toxicology 1987; 45: 53-64.
21. Kojima S, Shimada A, Morita T, Yamano Y, Umemura T. Localization of metallothioneins-I & -II and -III in the brain of aged dog. J. Vet. Med. Sci. 1999; 61: 343-349.
22. Holloway AF, Stennard FA, Dziegielewska KM, Weller L, West AK. Localisation and expression of metallothionein immunoreactivity in the developing sheep brain. Int. J. Dev. Neurosci. 1997; 15: 195-203.
23. Hanlon J, Monks E, Hughes C, Weavers E, Rogers M. Metallothionein in bovine spongiform encephalopathy. J. Comp. Pathol. 2002; 127: 280-289.
24. Itano Y, Noji S, Koyama E, et al. Bacterial endotoxin-induced expression of metallothionein genes in rat brain, as revealed by in situ hybridization. Neurosci. Lett. 1991; 124: 13-16.
25. Hao R, Cerutis DR, Blaxall HS, Rodriguez-Sierra JF, Pfeiffer RF, Ebadi M. Distribution of zinc metallothionein I mRNA in rat brain using in situ hybridization. Neurochem. Res. 1994; 19: 761-767.
26. Masters BA, Quaife CJ, Erickson JC, et al. Metallothionein III is expressed in neurons that sequester zinc in synaptic vesicles. J. Neurosci. 1994; 14: 5844-5857.
27. Carrasco J, Hernández J, González B, Campbell IL, Hidalgo J. Localization of metallothionein-I and -III expression in the CNS of transgenic mice with astrocyte-targeted expression of interleukin 6. Exp. Neurol. 1998; 153: 184-194.
28. Penkowa M, Carrasco J, Giralt M, Moos T, Hidalgo J. CNS wound healing is severely depressed in metallothionein I- and II-deficient mice. J. Neurosci. 1999; 19: 2535-2545.
29. Young JK, Garvey JS, Huang PC. Glial immunoreactivity for metallothionein in the rat brain. Glia 1991; 4: 602-610.
30. Suzuki K, Nakajima K, Otaki N, Kimura M. Metallothionein in developing human brain. Biol. Signals 1994; 3: 188-192.
31. Young JK. Glial metallothionein. Biol. Signals 1994; 3: 169-175.
32. Penkowa M, Moos T. Disruption of the blood-brain interface in neonatal rat neocortex induces a transient expression of metallothionein in reactive astrocytes. Glia 1995; 13: 217-227.
33. Nakajima K, Suzuki K. Immunochemical detection of metallothionein in brain. Neurochem. Int. 1995; 27: 73-87.
34. Shimada A, Yanagida M, Umemura T. An immunohistochemical study on the tissue-specific localization of metallothionein in dogs. J. Comp. Pathol. 1997; 116: 1-11.
35. Kawashima T, Adachi T, Tokunaga Y, et al. Immunohistochemical analysis in a case of idiopathic Lennox-Gastaut syndrome. Clin. Neuropathol. 1999; 18: 286-292.
36. Carrasco J, Giralt M, Penkowa M, Stalder AK, Campbell IL, Hidalgo J. Metallothioneins are upregulated in symptomatic mice with astrocyte-targeted expression of tumor necrosis factor-α. Exp. Neurol. 2000; 163: 46-54.
37. Acarin L, González B, Hidalgo J, Castro AJ, Castellano B. Primary cortical glial reaction versus secondary thalamic glial response in the excitotoxically injured young brain: astroglial response and metallothionein expression. Neuroscience 1999; 92: 827-839.
38. Nagano S, Satoh M, Sumi H, et al. Reduction of metallothioneins promotes the disease expression of familial amyotrophic lateral sclerosis mice in a dose-dependent manner. Eur. J. Neurosci. 2001; 13: 1363-1370.
39. Hidalgo J, Aschner M, Zatta P, Vašák M. Roles of the metallothionein family of proteins in the central nervous system. Brain. Res. Bull. 2001; 55: 133-145.
40. Uchida Y, Takio K, Titani K, Ihara Y, Tomonaga M. The growth inhibitory factor that is deficient in the Alzheimer's disease brain is a 68 amino acid metallothionein-like protein. Neuron 1991; 7: 337-347.
41. Tsuji S, Kobayashi H, Uchida Y, Ihara Y, Miyatake T. Molecular cloning of human growth inhibitory factor cDNA and its down-regulation in Alzheimer's disease. Embo. J. 1992; 11: 4843-4850.
42. Kobayashi H, Uchida Y, Ihara Y, et al. Molecular cloning of rat growth inhibitory factor cDNA and the expression in the central nervous system. Mol. Brain Res. 1993; 19: 188-194.
43. Hoey JG, Garrett SH, Sens MA, Todd JH, Sens DA. Expression of MT-3 mRNA in human kidney, proximal tubule cell cultures, and renal cell carcinoma. Toxicol. Lett. 1997; 92: 149-160.
44. Moffatt P, Séguin C. Expression of the gene encoding metallothionein-3 in organs of the reproductive system. DNA Cell Biol. 1998; 17: 501-510.
45. Garrett SH, Sens MA, Todd JH, Somji S, Sens DA. Expression of MT-3 protein in the human kidney. Toxicol. Lett. 1999; 105: 207-214.
46. Garrett SH, Sens MA, Shukla D, et al. Metallothionein isoform 3 expression in the human prostate and cancer-derived cell lines. Prostate 1999; 41: 196-202.
47. Sens MA, Somji S, Garrett SH, Beall CL, Sens DA. Metallothionein isoform 3 overexpression is associated with breast cancers having a poor prognosis. Am. J. Pathol. 2001; 159: 21-26.
48. Cyr DG, Dufresne J, Pillet S, Alfieri TJ, Hermo L. Expression and regulation of metallothioneins in the rat epididymis. J. Androl. 2001; 22: 124-135.
49. Yamashita M, Glasgow E, Zhang BJ, Kusano K, Gainer H. Identification of cell-specific messenger ribonucleic acids in oxytocinergic and vasopressinergic magnocellular neurons in rat supraoptic nucleus by single-cell differential hybridization. Endocrinology 2002; 143: 4464-4476.
50. Pountney DL, Fundel SM, Faller P, Birchler NE, Hunziker P, Vasak M. Isolation, primary structures and metal binding properties of neuronal growth inhibitory factor (GIF) from bovine and equine brain. FEBS Lett. 1994; 345: 193-197.
51. Dalton T, Pazdernik TL, Wagner J, Samson F, Andrews GK. Temporalspatial patterns of expression of metallothionein-I and -III and other stress related genes in rat brain after kainic acid-induced seizures. Neurochem. Int. 1995; 27: 59-71.
52. Chen CF, Wang SH, Lin LY. Identification and characterization of metallothionein III (growth inhibitory factor) from porcine brain. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 1996; 115: 27-32.
53. Kojima S, Shimada A, Kodan A, et al. Molecular cloning and expression of the canine metallothionein-III gene. Can. J. Vet. Res. 1998; 62: 148-151.
54. Chung RS, Holloway AF, Eckhardt BL, et al. Sheep have an unusual variant of the brain-specific metallothionein, metallothionein-III. Biochem. J. 2002; 365: 323-328.
55. Uchida Y. Growth inhibitory factor in brain. In: Metallothionein III (eds. Kt Suzuki, N Imura, M Kimura), pp. 315-328. Birkhäuser Verlag, Basel, 1993.
56. Anezaki T, Ishiguro H, Hozumi I, et al. Expression of growth inhibitory factor (GIF) in normal and injured rat brains. Neurochem. Int. 1995; 27: 89-94.
57. Yuguchi T, Kohmura E, Yamada K, et al. Expression of growth inhibitory factor mRNA following cortical injury. J. Neurotrauma 1995; 12: 299-306.
58. Yuguchi T, Kohmura E, Yamada K, et al. Changes in growth inhibitory factor mRNA expression compared with those in c-jun mRNA expression following facial nerve transection. Mol. Brain Res. 1995; 28: 181-185.
59. Zheng H, Berman NE, Klaassen CD. Chemical modulation of metallothionein I and III mRNA in mouse brain. Neurochem. Int. 1995; 27: 43-58.
60. Choudhuri S, Kramer KK, Berman NE, Dalton TP, Andrews GK, Klaassen CD. Constitutive expression of metallothionein genes in mouse brain. Toxicol. Appl. Pharmacol. 1995; 131: 144-154.
61. Yuguchi T, Kohmura E, Sakaki T, et al. Expression of growth inhibitory factor mRNA after focal ischemia in rat brain. J. Cereb. Blood Flow Metab. 1997; 17: 745-752.
62. Carrasco J, Hernández J, Bluethmann H, Hidalgo J. Interleukin-6 and tumor necrosis factor-alpha type 1 receptor deficient mice reveal a role of IL-6 and TNF-alpha on brain metallothionein-I and -III regulation. Mol. Brain Res. 1998; 57: 221-234.
63. Kojima S, Shimada A, Morita T, Yamano Y, Umemura T. Localization of metallothioneins-I & -II and -III in the brain of aged dog. J. Vet. Med. Sci. 1999; 61: 343-349.
64. Velázquez RA, Cai Y, Shi Q, Larson AA. The distribution of zinc selenite and expression of metallothionein-III mRNA in the spinal cord and dorsal root ganglia of the rat suggest a role for zinc in sensory transmission. J. Neurosci. 1999; 19: 2288-2300.
65. Acarin L, Carrasco J, González B, Hidalgo J, Castellano B. Expression of growth inhibitory factor (metallothionein-III) mRNA and protein following excitotoxic immature brain injury. J. Neuropathol. Exp. Neurol. 1999; 58: 389-397.
66. Penkowa M, Moos T, Carrasco J, et al. Strongly compromised inflammatory response to brain injury in interleukin-6-deficient mice. Glia 1999; 25: 343-357.
67. Gong YH, Elliott JL. Metallothionein expression is altered in a transgenic murine model of familial amyotrophic latyeral sclerosis. Exp. Neurol. 2000; 162: 27-36.
68. Kim D, Kim EH, Kim C, et al. Differential regulation of metallothionein-I, II, and III mRNA expression in the rat brain following kainic acid treatment. Neuroreport 2003; 14: 679-682.
69. Yamada M, Hayashi S, Hozumi I, Inuzuka T, Tsuji S, Takahashi H. Subcellular localization of growth inhibitory factor in rat brain: light and electron microscopic immunohistochemical studies. Brain Res. 1996; 735: 257-264.
70. Hozumi I, Inuzuka T, Ishiguro H, Hiraiwa M, Uchida Y, Tsuji S. Immunoreactivity of growth inhibitory factor in normal rat brain and after stab wounds-an immunocytochemical study using confocal laser scan microscope. Brain Res. 1996; 741: 197-204.
71. Carrasco J, Giralt M, Molinero A, Penkowa M, Moos T, Hidalgo J. Metallothionein (MT)-III: generation of polyclonal antibodies, comparison with MT-I+II in the freeze lesioned rat brain and in a bioassay with astrocytes, and analysis of Alzheimer's disease brains. J. Neurotrauma. 1999; 16: 1115-1129.
72. Kawashima T, Doh-ura K, Torisu M, Uchida Y, Furuta A, Iwaki T. Differential expression of metallothioneins in human prion diseases. Dement. Geriatr. Cogn. Disord. 2000; 11: 251-262.
73. Isumi H, Uchida Y, Hayashi T, Furukawa S, Takashima S. Neuron death and glial response in pontosubicular necrosis. The role of the growth inhibition factor. Clin. Neuropathol. 2000; 19: 77-84.
74. Penkowa M, Giralt M, Thomsen P, Carrasco J, Hidalgo J. Zinc or copper deficiency-induced impaired inflammatory response to brain trauma may be caused by the concomitant metallothionein changes. J. Neurotrauma 2001; 18: 447-463.
75. Yanagitani S, Miyazaki H, Nakahashi Y, et al. Ischemia induces metallothionein III expression in neurons of rat brain. Life Sci. 1999; 64: 707-715.
76. Yu WH, Lukiw WJ, Bergeron C, Niznik HB, Fraser PE. Metallothionein III is reduced in Alzheimer's disease. Brain Res. 2001; 894: 37-45.
77. Lee JY, Kim JH, Palmiter RD, Koh JY. Zinc released from metallothionein-III may contribute to hippocampal CA1 and thalamic neuronal death following acute brain injury. Exp. Neurol. 2003; 184: 337-347.
78. Miyazaki I, Asanuma M, Higashi Y, Sogawa CA, Tanaka K, Ogawa N. Age-related changes in expression of metallothionein-III in rat brain. Neurosci. Res. 2002; 43: 323-333.
79. Duguid JR, Bohmont CW, Liu NG, Tourtellotte WW. Changes in brain gene expression shared by scrapie and Alzheimer disease. Proc. Natl. Acad. Sci. USA 1989; 86: 7260-7264.
80. Zambenedetti P, Giordano R, Zatta P. Metallothioneins are highly expressed in astrocytes and microcapillaries in Alzheimer's disease. J. Chem. Neuroanat. 1998; 15: 21-26.
81. Adlard PA, West AK, Vickers JC. Increased density of metallothionein I/II-immunopositive cortical glial cells in the early stages of Alzheimer's disease. Neurobiol. Dis. 1998; 5: 349-356.
82. Chuah MI, Getchell ML. Metallothionein in olfactory mucosa of Alzheimer's disease patients and apoE-deficient mice. Neuroreport 1999; 10: 1919-1924.
83. Sillevis Smitt PA, Blaauwgeers HG, Troost D, de Jong JM. Metallothionein immunoreactivity is increased in the spinal cord of patients with amyotrophic lateral sclerosis. Neurosci. Lett. 1992; 144: 107-110.
84. Sillevis Smitt PA, Mulder TP, Verspaget HW, Blaauwgeers HG, Troost D, de Jong JM. Metallothionein in amyotrophic lateral sclerosis. Biol. Signals 1994; 3: 193-197.
85. Blaauwgeers HG, Anwar Chand M, van den Berg FM, Vianney de Jong JM, Troost D. Expression of different metallothionein messenger ribonucleic acids in motor cortex, spinal cord and liver from patients with amyotrophic lateral sclerosis. J. Neurol. Sci. 1996; 142: 39-44.
86. Lock C, Hermans G, Pedotti R, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 2002; 8: 500-508.
87. Penkowa M, Espejo C, Ortega-Aznar A, Hidalgo J, Montalban X, Martínez-Cáceres EM. Metallothionein expression in the central nervous system of multiple sclerosis patients. Cell. Mol. Life Sci. 2003; 60: 1258-1266.
88. De SK, McMaster MT, Andrews GK. Endotoxin induction of murine metallothionein gene expression. J. Biol. Chem. 1990; 265: 15267-15274.
89. Hidalgo J, Borras M, Garvey JS, Armario A. Liver, brain, and heart metallothionein induction by stress. J. Neurochem. 1990; 55: 651-654.
90. Gasull T, Giralt M, García A, Hidalgo J. Regulation of metallothionein-I+II levels in specific brain areas and liver in the rat: role of catecholamines. Glia 1994; 12: 135-143.
91. Jacob ST, Ghoshal K, Sheridan JF. Induction of metallothionein by stress and its molecular mechanisms. Gene Expr. 1999; 7: 301-310.
92. Hidalgo J, Castellano B, Campbell IL. Regulation of brain metallothioneins. Current Topics Neurochem. 1997; 1: 1-26.
93. Montpied P, de Bock F, Baldy Moulinier M, Rondouin G. Alterations of metallothionein II and apolipoprotein J mRNA levels in kainate-treated rats. Neuroreport 1998; 9: 79-83.
94. Carrasco J, Penkowa M, Hadberg H, Molinero A, Hidalgo J. Enhanced seizures and hippocampal neurodegeneration following kainic acid induced seizures in metallothionein-I+II deficient mice. Eur. J. Neurosci. 2000; 12: 2311-2322.
95. Tang Y, Lu A, Aronow BJ, Wagner KR, Sharp FR. Genomic responses of the brain to ischemic stroke, intracerebral haemorrhage, kainate seizures, hypoglycemia, and hypoxia. Eur. J. Neurosci. 2002; 15: 1937-1952.
96. Neal JW, Singhrao SK, Jasani B, Newman GR. Immunocytochemically detectable metallothionein is expressed by astrocytes in the ischaemic human brain. Neuropathol. Appl. Neurobiol. 1996; 22: 243-247.
97. van Lookeren Campagne M, Thibodeaux H, van Bruggen N, et al. Evidence for a protective role of metallothionein-I in focal cerebral ischemia. Proc. Natl. Acad. Sci. USA 1999; 96: 12870-12875.
98. Trendelenburg G, Prass K, Priller J, et al. Serial analysis of gene expression identifies metallothionein-II as major neuroprotective gene in mouse focal cerebral ischemia. J. Neurosci. 2002; 22: 5879-5888.
99. Fukada K, Nagano S, Satoh M, et al. Stabilization of mutant Cu/Zn superoxide dismutase (SOD1) protein by coexpressed wild SOD1 protein accelerates the disease progression in familial amyotrophic lateral sclerosis mice. Eur. J. Neurosci. 2001; 14: 2032-2036.
100. Puttaparthi K, Gitomer WL, Krishnan U, Son M, Rajendran B, Elliott JL. Disease progression in a transgenic model of familial amyotrophic lateral sclerosis is dependent on both neuronal and non-neuronal zinc binding proteins. J. Neurosci. 2002; 22: 8790-8796.
101. Penkowa M, Hidalgo J. Metallothionein I+II expression and their role in experimental autoimmune encephalomyelitis. Glia 2000; 32: 247-263.
102. Espejo C, Carrasco J, Hidalgo J, et al. Differential expression of metallothioneins in the CNS of mice with experimental autoimmune encephalomyelitis. Neuroscience 2001; 105: 1055-1065.
103. Penkowa M, Espejo C, Martínez-Cáceres EM, Poulsen CB, Montalban X, Hidalgo J. Altered inflammatory response and increased neurodegeneration in metallothionein I+II deficient mice during experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2001; 119: 248-260.
104. Penkowa M, Hidalgo J, Moos T. Increased astrocytic expression of metallothioneins I+II in brainstem of adult rats treated with 6-aminonicotinamide. Brain Res. 1997; 774: 256-259.
105. Penkowa M, Giralt M, Moos T, Thomsen PS, Hernández J, Hidalgo J. Impaired inflammatory response to glial cell death in genetically metallothionein-I- and -II-deficient mice. Exp. Neurol. 1999; 156: 149-164.
106. Penkowa M, Hidalgo J. IL-6 deficiency leads to reduced metallothionein-I+II expression and increased oxidative stress in the brain stem after 6-aminonicotinamide treatment. Exp. Neurol. 2000; 163: 72-84.
107. Coyle J, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993; 262: 689-695.
108. Hopkins S, Rothwell N. Cytokines and the nervous system. I: Expression and recognition. Trends Neurosci. 1995; 18: 83-88.
109. Rothwell NJ, Hopkins SJ. Cytokines and the nervous system II: actions and mechanisms of action. Trends Neurol. Sci. 1995; 18: 130-136.
110. Stichel C, Verner Müller H. Experimental strategies to promote axonal regeneration after traumatic central nervous system injury. Progr. Neurobiol. 1998; 56: 119-148.
111. McIntosh T, Juhler M, Wieloch T. Novel pharmacologic strategies in the treatment of experimental traumatic brain injury. J. Neurotrauma 1998; 15: 731-769.
112. Campbell IL, Abraham CR, Masliah E, et al. Neurologic disease in transgenic mice by cerebral overexpression of interleukin 6. Proc. Natl. Acad. Sci. USA 1993; 90: 10061-10065.
113. Stalder AK, Carson MJ, Pagenstecher A, et al. Late-onset chronic inflammatory encephalopathy in immune-competent and severe combined immune-deficient (SCID) mice with astrocyte-targeted expression of tumor necrosis factor. Am. J. Pathol. 1998; 153: 767-783.
114. Hernández J, Molinero A, Campbell IL, Hidalgo J. Transgenic expression of interleukin 6 in the central nervous system regulates brain metallothionein-I and -III expression in mice. Brain. Res. Mol. Brain. Res. 1997; 48: 125-131.
115. Giralt M, Carrasco J, Penkowa M, et al. Astrocyte-targeted expression of interleukin-3 and interferon-a causes specific changes in metallothionein expression in the brain. Exp. Neurol. 2001; 168: 334-346.
116. Sato M, Bremner I. Oxygen free radicals and metallothionein. Free Radical Biol. Med. 1993; 14: 325-337.
117. Aschner M. The functional significance of brain metallothioneins. Faseb J. 1996; 10: 1129-1136.
118. Lee DK, Carrasco J, Hidalgo J, Andrews GK. Identification of a signal transducer and activator of transcription (STAT) binding site in the mouse metallothionein-I promoter involved in interleukin-6-induced gene expression. Biochem. J. 1999; 337: 59-65.
119. Palmiter RD, Sandgren EP, Koeller DM, Brinster RL. Distal regulatory elements from the mouse metallothionein locus stimulate gene expression in transgenic mice. Mol. Cell. Biol. 1993; 13: 5266-5275.
120. Michalska AE, Choo KH. Targeting and germ-line transmission of a null mutation at the metallothionein I and II loci in mouse. Proc. Natl. Acad. Sci. USA 1993; 90: 8088-8092.
121. Masters BA, Kelly EJ, Quaife CJ, Brinster RL, Palmiter RD. Targeted disruption of metallothionein I and II genes increases sensitivity to cadmium. Proc. Natl. Acad. Sci. USA 1994; 91: 584-588.
122. Penkowa M, Giralt M, Camats J, Hidalgo J. Metallothionein 1+2 protect the CNS during neuroglial degeneration induced by 6-aminonicotinamide. J. Comp. Neurol. 2002; 444: 174-189.
123. Asanuma M, Miyazaki I, Higashi Y, et al. Aggravation of 6-hydroxydopamine-induced dopaminergic lesions in metallothionein-I and -II knock-out mouse brain. Neurosci. Lett. 2002; 327: 61-65.
124. Penkowa M, Espejo C, Martinez-Cáceres EM, Montalban X, Hidalgo J. Increased demyelination and axonal damage in metallothionein I+II-deficient mice during experimental autoimmune encephalomyelitis. Cell. Mol. Life Sci. 2003; 60: 185-197.
125. Penkowa M, Carrasco J, Giralt M, et al. Altered central nervous system cytokine-growth factor expression profiles and angiogenesis in metallothionein-I+II deficient mice. J. Cereb. Blood Flow Metab. 2000; 20: 1174-1189.
126. Giralt M, Penkowa M, Lago N, Molinero A, Hidalgo J. Metallothionein-1+2 protect the CNS after a focal brain injury. Exp. Neurol. 2002; 173: 114-128.
127. Giralt M, Penkowa M, Hernández J, et al. Metallothionein-1+2 deficiency increases brain pathology in transgenic mice with astrocyte-targeted expression of interleukin 6. Neurobiol. Dis. 2002; 9: 319-338.
128. Molinero A, Penkowa M, Hernández J, et al. Metallothionein-1 overexpression decreases brain pathology in transgenic mice with astrocyte-targeted expression of interleukin 6. J. Neuropathol. Exp. Neurol. 2003; 62: 315-328.
129. Penkowa M, Camats J, Giralt M, et al. Metallothionein-I overexpression alters brain inflammation and stimulates brain repair in transgenic mice with astrocyte-targeted interleukin-6 expression. Glia 2003; 42: 287-306.
130. Penkowa M, Hidalgo J. Treatment with metallothionein prevents demyelination and axonal damage and increases oliogodendrocyte precursors and tissue reapir during experimental autoimmune encephalomyelitis (EAE). J. Neurosci. Res. 2003; 72: 574-586.
131. Chung RS, Vickers JC, Chuah MI, West AK. Metallothionein-IIA promotes initial neurite elongation and postinjury reactive neurite growth and facilitates healing after focal cortical brain injury. J. Neurosci. 2003; 23: 3336-3342.
132. Erickson JC, Sewell AK, Jensen LT, Winge DR, Palmiter RD. Enhanced neurotrophic activity in Alzheimer's disease cortex is not associated with down-regulation of metallothionein-III (GIF). Brain Res. 1994; 649: 297-304.
133. Amoureux MC, Van Gool D, Herrero MT, Dom R, Colpaert FC, Pauwels PJ. Regulation of metallothionein-III (GIF) mRNA in the brain of patients with Alzheimer disease is not impaired. Mol. Chem. Neuropathol. 1997; 32: 101-121.
134. Uchida Y. Growth-inhibitory factor, metallothionein-like protein, and neurodegenerative diseases. Biol. Signals 1994; 3: 211-215.
135. Arai Y, Uchida Y, Takashima S. Developmental immunohistochemistry of growth inhibitory factor in normal brains and brains of patients with Down syndrome. Pediatr. Neurol. 1997; 17: 134-138.
136. Hozumi I, Inuzuka T, Hiraiwa M, et al. Changes of growth inhibitory factor after stab wounds in rat brain. Brain Res. 1995; 688: 143-148.
137. Inuzuka T, Hozumi I, Tamura A, Hiraiwa M, Tsuji S. Patterns of growth inhibitory factor (GIF) and glial fibrillary acidic protein relative level changes differ following left middle cerebral artery occlusion in rats. Brain Res. 1996; 709: 151-153.
138. Erickson JC, Masters BA, Kelly EJ, Brinster RL, Palmiter RD. Expression of human metallothionein-III in transgenic mice. Neurochem. Int. 1995; 27: 35-41.
139. Erickson JC, Hollopeter G, Thomas SA, Froelick GJ, Palmiter RD. Disruption of the metallothionein-III gene in mice: analysis of brain zinc, behavior, and neuron vulnerability to metals, aging, and seizures. J. Neurosci. 1997; 17: 1271-1281.
140. Montoliu C, Monfort P, Carrasco J, et al. Metallothionein-III prevents glutamate and nitric oxide neurotoxicity in primary cultures of cerebellar neurons. J. Neurochem. 2000; 75: 266-273.
141. Chen Y, Irie Y, Keung WM, Maret W. S-Nitrosothiols React Preferentially with Zinc Thiolate Clusters of Metallothionein III through Transnitrosation. Biochemistry 2002; 41: 8360-8367.
142. Ren H, Ji Q, Liu Y, Ru B. Different protective roles in vitro of alpha- and beta-domains of growth inhibitory factor (GIF) on neuron injuries caused by oxygen free radicals. Biochim. Biophys. Acta 2001; 1568: 129-134.
143. Irie Y, Keung WM. Metallothionein-III antagonizes the neurotoxic and neurotrophic effects of amyloid beta peptides. Biochem. Biophys. Res. Commun. 2001; 282: 416-420.
144. Irie Y, Keung WM. Anti-amyloid beta activity of metallothionein-III is different from its neuronal growth inhibitory activity: structure-activity studies. Brain Res. 2003; 960: 228-234.
145. Uchida Y, Gomi F, Masumizu T, Miura Y. Growth inhibitory factor prevents neurite extension and death of cortical neurons caused by high oxygen exposure through hydroxyl radical scavenging. J. Biol. Chem. 2002; 277: 32353-32359.
146. Shi Y, Wang W, Mo J, Du L, Yao S, Tang W. Interactions of growth inhibitory factor with hydroxyl and superoxide radicals. Biometals 2003; 16: 383-389.
147. Roschitzki B, Vasak M. Redox labile site in a Zn4 cluster of Cu4,Zn4-metallothionein-3. Biochemistry 2003; 42: 9822-9828.
148. Sakamoto T, Kawazoe Y, Uchida Y, Hozumi I, Inuzuka T, Watabe K. Growth inhibitory factor prevents degeneration of injured adult rat motoneurons. Neuroreport 2003; 14: 2147-2151.
149. Carrasco J, Penkowa M, Giralt M, et al. Role of metallothionein-III following central nervous system damage. Neurobiol. Dis. 2003; 13: 22-36.
150. Bibel M, Barde Y-A. Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system. Genes & Develop. 2000; 14: 2919-2937.
151. Benowitz LI, Routtenberg A. GAP-43: an intrinsec determinant of neuronal development and plasticity. Trends. Neurosci. 1997; 20: 84-91.
152. Sewell AK, Jensen LT, Erickson JC, Palmiter RD, Winge DR. Bioactivity of metallothionein-3 correlates with its novel beta domain sequence rather than metal binding properties. Biochemistry 1995; 34: 4740-4747.
153. Chung RS, Vickers JC, Chuah MI, Eckhardt BL, West AK. Metallothionein-III inhibits initial neurite formation in developing neurons as well as postinjury, regenerative neurite sprouting. Exp. Neurol. 2002; 178: 1-12.
154. Chung RS, West AK. A role for extracellular metallothioneins in CNS injury and repair. Neuroscience 2004; 123: 595-599.
155. Ceballos D, Lago N, Verdu E, et al. Role of metallothioneins in peripheral nerve function and regeneration. Cell. Mol. Life Sci. 2003; 60: 1209-1216.